
Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The Lancet Child & Adolescent Health journal.This article was originally […]